CN1889853A - 包含谷氨酰胺的抗腹泻组合物 - Google Patents
包含谷氨酰胺的抗腹泻组合物 Download PDFInfo
- Publication number
- CN1889853A CN1889853A CNA2004800360410A CN200480036041A CN1889853A CN 1889853 A CN1889853 A CN 1889853A CN A2004800360410 A CNA2004800360410 A CN A2004800360410A CN 200480036041 A CN200480036041 A CN 200480036041A CN 1889853 A CN1889853 A CN 1889853A
- Authority
- CN
- China
- Prior art keywords
- composition
- meals
- glutamine
- weight
- food
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 230000001142 anti-diarrhea Effects 0.000 title claims abstract description 5
- 239000000835 fiber Substances 0.000 claims abstract description 31
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 16
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 15
- 241000124008 Mammalia Species 0.000 claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 claims abstract description 10
- 230000004054 inflammatory process Effects 0.000 claims abstract description 10
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 8
- 235000012054 meals Nutrition 0.000 claims description 33
- 238000000855 fermentation Methods 0.000 claims description 18
- 230000004151 fermentation Effects 0.000 claims description 18
- 241000282326 Felis catus Species 0.000 claims description 15
- 239000000194 fatty acid Substances 0.000 claims description 12
- 206010012735 Diarrhoea Diseases 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 3
- 235000020660 omega-3 fatty acid Nutrition 0.000 abstract description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 229940012843 omega-3 fatty acid Drugs 0.000 abstract 1
- 235000013305 food Nutrition 0.000 description 37
- 239000002689 soil Substances 0.000 description 14
- 235000006708 antioxidants Nutrition 0.000 description 11
- 108010062580 Concanavalin A Proteins 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001842 enterocyte Anatomy 0.000 description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 230000003190 augmentative effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000003226 mitogen Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 238000007696 Kjeldahl method Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 235000019784 crude fat Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000000527 lymphocytic effect Effects 0.000 description 2
- 230000003526 lymphopoietic effect Effects 0.000 description 2
- 235000021049 nutrient content Nutrition 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013324 preserved food Nutrition 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 235000003130 Arctium lappa Nutrition 0.000 description 1
- 235000008078 Arctium minus Nutrition 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 235000016068 Berberis vulgaris Nutrition 0.000 description 1
- 241000335053 Beta vulgaris Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 244000182067 Fraxinus ornus Species 0.000 description 1
- 235000002917 Fraxinus ornus Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 229920000294 Resistant starch Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 201000009840 acute diarrhea Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 241001233037 catfish Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000021238 nutrient digestion Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000021254 resistant starch Nutrition 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
- 150000004823 xylans Chemical class 0.000 description 1
- 229960003487 xylose Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/22—Comminuted fibrous parts of plants, e.g. bagasse or pulp
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
- A23L33/24—Cellulose or derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Zoology (AREA)
- Animal Husbandry (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Birds (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了在患有胃肠道炎症的哺乳动物中适合于哺乳动物口服摄取的组合物，其包括抗腹泻有效量的谷氨酰胺、发酵性纤维、抗氧化剂和ω－3脂肪酸。
Description
发明背景
保持哺乳动物胃肠道的状态良好是非常令人期望的目标。特别的烦恼在于胃肠道的炎性状况。胃肠道炎症的一些征候包括急性或慢性腹泻、软便、便血、呕吐、营养物质消化和吸收差、体重减轻和食欲不振。已知疾病如胃炎、肠炎、结肠炎、炎症性肠病、溃疡、某些类型的癌症、和已知的以GI炎症作为其主要构成的其它病症。
我们发现某些物质的混合物可以带来GI炎症的基本征候如腹泻的改善。当对哺乳动物口服给用适当量的谷氨酰胺、发酵性纤维、抗氧化剂和ω(n)-3脂肪酸时，在胃肠道炎症得到改善的同时，排便频率以及排便的质量可以得到显著改善，特别是在伴侣宠物如猫中。
发明简述
根据本发明，提供了在患有胃肠道炎症的哺乳动物中适合于哺乳动物口服摄取的组合物，该组合物包括抗腹泻有效量的谷氨酰胺、发酵性纤维、抗氧化剂和ω-3脂肪酸的组合。
本发明的另一个方面是处理患有胃肠道炎症的哺乳动物中的腹泻的方法，包括对哺乳动物口服给用上述组合物。
发明详述
公知谷氨酰胺对于淋巴细胞的增殖是重要物质并且是肠细胞的重要营养物质。谷氨酰胺还是谷胱甘肽的前体，谷胱甘肽为体内的天然抗氧化剂。本文中公开的用于任何组分的所有重量％都基于哺乳动物的日常膳食。所有的数字都以干物质组成计算。
谷氨酰胺的量最低为约0.1、0.15或0.2重量％。最大量通常不超过约5、4或3重量％。
可以使用的纤维是具有适度发酵性的纤维、高度发酵性的纤维、或为两者的混合物。也可在不影响制剂效果的低水平下加入低发酵性或非发酵性的纤维。
我们已经表明，某些益生纤维组分当被狗和猫胃肠道中存在的细菌发酵时产生大量的丁酸脂和其它短链脂肪酸，其将酸化胃肠道并降低病原体的生长。产生大量丁酸酯的益生纤维包括但不限于甘露寡聚糖、胶质、寡木糖、牛蒡、甜菜浆、菊粉、半乳糖、其它木聚糖、果聚糖、右旋糖酐、β葡聚糖、抗性淀粉、得自胶类的多糖等，在膳食中应当以约0.5-20重量％的量存在，优选为约1-5重量％。胶类可包括由微生物产生的胶类如洁冷胶、黄原胶或由植物产生的胶类如阿拉伯树胶。混合物的配制优选基于高的丁酸酯生成和基于挥发性脂肪酸(VFA)生成的中等发酵能力和有机物质消失率，以帮助保持最佳的GI健康。组合物可以包括至少约10-60％的适度发酵性纤维和约20-40％的高度发酵性纤维。这些纤维应选择为使得这些纤维的丁酸酯生成量较高，为总VFA的约5-40％。适度发酵性纤维的定义为当由粪便细菌体外发酵24小时周期时有机物质消失率为约15到60％。也就是说，最初存在的总有机物质的约15到60％被粪便细菌发酵和被转换掉。高度发酵性纤维具有大于60％的消失率。
在组合物和方法中还可使用抗氧化剂。可以使用维生素E、C及其掺混物。可使用这些维生素的任何前体，诸如醋酸生育酚和抗坏血酸钠。维生素E最低为膳食的约0.1、0.2或0.4重量％，通常最大不超过膳食的约3、2或1重量％。维生素C最低为膳食的约0.1、0.2或0.4重量％，通常最大不超过膳食的约3、2或1重量％。
ω-3脂肪酸是公知的膳食组分，主要在油类和脂类中发现，特别是在鱼油诸如鲱鱼、鲑鱼等鱼油中。ω-3脂肪酸的基本组分为二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)和α-亚麻酸(ALA)。ω-3脂肪酸的量通常为最低约0.1、0.2或0.5重量％，通常最大不超过约3、2和1重量％。通常还存在于油类和脂类中的是ω-6脂肪酸。当存在时，ω-6脂肪酸对ω-3脂肪酸的比以重量计为约0.5∶1到6∶1，优选约2∶1到4∶1。
以下实施例说明使用本发明的组合物在处置哺乳动物的腹泻时实现的益处。哺乳动物患有或可患有胃肠道炎症(优选炎症性肠病)。
实施例1
在以下研究中，用2种食品喂养患有炎症性肠病(IBD)的12只猫，各自喂养2周。对6只猫喂养食品A2周，对6只猫喂养食品B2周，之后交叉喂养。每日监控粪便质量，并基于1-5等级进行评分，1分为过稀且多水，5分为坚硬且成形。评分如下。得自患有IBD的猫的粪便通常为1或2分。
粪便监控评分
1：多水
2：软，未成形
3：软，成形，湿润
4：坚硬，成形，干燥
5：坚硬，干燥小球
表1表明膳食对患有慢性腹泻的猫的粪便质量的作用。表1表示获得1-5分的粪便百分数。第一罐装食品A包含3％的低发酵能力(低于15％)的纤维，罐装食品B包含1.5％的高发酵能力(高于约60％)的纤维，食品的营养含量如下所示。
| 食品A | 食品B | |
| 低发酵性纤维食品 | 高发酵性纤维食品 | |
| 湿度 | 72.69 | 72.58 |
| 蛋白质-凯氏法 | 8.24 | 7.94 |
| 粗纤维 | 0.3 | 0.2 |
| 酸解的粗脂肪 | 9.58 | 9.85 |
结果
结果表明，喂养含有高发酵性纤维源的食品B改善猫的粪便质量，从42％的粪便百分数(得分为1和2分)改善到仅仅15％的粪便百分数(得分为1和2分)。
表1
| 粪便％ | ||
| 食品A | 食品B* | |
| 粪便质量评分 | 低发酵性纤维食品 | 高发酵性纤维食品 |
| 1 | 11 | 2 |
| 2 | 31 | 13 |
| 3 | 41 | 45 |
| 4 | 10 | 22 |
| 5 | 7 | 14 |
*4％的粪便不能用于等级评价
实施例2
表2表示实施例1中的相同猫用2种不同食品喂养进行研究的数据。两种食品都含有类似量的益生纤维和ω-3脂肪酸。食品C含有额外的谷氨酰胺和抗氧化剂，而食品D不含有额外的谷氨酰胺或抗氧化剂。半数猫喂养食品C2周，另外半数猫喂养食品D，然后所有猫有1周的冲洗期。然后交叉喂养另一种食品，再喂养2周。表2的结果表明，与当对猫喂养食品D(该膳食没有额外的谷氨酰胺和抗氧化剂)的粪便质量相比(得分为1和2的粪便百分数为7％)，当对猫喂养含有谷氨酰胺和高抗氧化剂的食品C时，粪便质量有显著改善(得分为1和2的粪便百分数为0％)。与食品A(得分为1和2的粪便百分数为42％)相比，食品C的粪便质量具有显著更好的结果，得分为1和2的粪便百分数为0％。食品C还显著好于食品B(得分为1和2的粪便百分数为15％)。食品C还显著好于食品D(得分为1和2的粪便百分数为7％)。食品C具有本发明所有的显著组分：谷氨酰胺、抗氧化剂、发酵性纤维和n-3脂肪酸。食品A、B和D都缺少这些组分中的至少一种。
食品的营养含量如下所示。
| 组成 | 所有选项(食品C) | 所有选项，除了谷氨酰胺和抗氧化剂(食品D) |
| 湿度％ | 75-76 | 75-76 |
| 蛋白质-凯氏法％ | 10 | 10.1 |
| 粗纤维％ | 0.2 | 0.4 |
| 灰分％ | 1.49 | 1.69 |
| 粗脂肪％ | 4-6 | 4-6 |
| 不溶性纤维％ | 1-1.5 | 1-1.5 |
| 可溶性纤维％ | 0.1-0.3 | 0.1-0.3 |
| ω-3(计算值) | 0.13 | 0.06 |
| ω-6(计算值) | 1.51 | 0.46 |
| 抗坏血酸μg/g | 30-50 | 4-10 |
| 总生育酚μg/ml | 300-400 | 30-50 |
表2
粪便百分数
| 粪便重量评分 | 食品C[所有选项] | 食品[所有选项，除了谷氨酰胺和抗氧化剂] |
| 1 | 0 | 0 |
| 2 | 0 | 7 |
| 3 | 29 | 67 |
| 4 | 58 | 27 |
| 5 | 13 | 1 |
数据表明具有额外的谷氨酰胺和抗氧化剂的膳食在这些猫中持续维持粪便质量的改善。
实施例3
以下实验表明在上述实施例中使用的谷氨酰胺源具有生物利用度，并且能够激发免疫功能。谷氨酰胺是肠道的重要营养物质，因为其是肠细胞和淋巴细胞的重要能量来源。膳食中的大部分谷氨酰胺被肠细胞以及肠中的免疫细胞所吸收。
在一个实验中，试验了谷氨酰胺的来源，看看其是否具有生物利用度并且能够递送足够的谷氨酰胺到肠细胞。谷氨酰胺的来源是小麦水解产物，其富集30％的谷氨酰胺。在6只狗中进行剂量反应研究，看看在喂养膳食后在血浆中是否可检测到增加量的谷氨酰胺源(0、0.5、1.0、2％的谷氨酰胺含量)。
表3
在用增补有不同量的谷氨酰胺的食品喂养的动物中，饭后血浆谷氨酰胺的变化
| 增补的谷氨酰胺％ | 饭后血浆谷氨酰胺相对于对照的变化％ |
| 0.5％ | 3 |
| 1.0％ | 10 |
| 2.0％ | 15 |
数据表明对膳食中增加量的谷氨酰胺有增加的反应，特别是在饭后30分钟。由此可见，谷氨酰胺在被肠细胞摄取后可被血流获得。
在另一个实验中，检测了谷氨酰胺作为免疫调节剂的效力。随机将20只小猎犬分成4组，它们接受基本膳食或增补有1％、2％或者4％谷氨酰胺的基本膳食。在第1天和第16天，在动物停食后2小时抽取血样在肝素化试管中，样品用于免疫测量(T细胞增生试验)。
T细胞增殖试验。使用Nova Celltrak II(Beckman Coulter Corp.，FL)计数每个血样中的外周血液白细胞(PBL)。血液用补给性培养基稀释(1∶20)，将稀释后的血液涂板在96孔细胞培养物板中，一式三份，细胞培养物板具有在补给性培养基中稀释的以下促分裂素：伴刀豆球蛋白A(0.5μg/ml，2.5μg/ml，和10μg/ml)、PWM(1.5μg/ml、2.5μg/ml)、和PHA(0.5μg/ml、2.5μg/ml)。将板在包含7％CO2的湿润培养箱中在37℃培养72小时。细胞DNA为Ci/孔[在用13H收集之前脉冲标记18小时]胸苷。细胞DNA在玻璃纤维纸上使用细胞收集器(Skatron Instruments Inc.，VA)收集并使用1.5毫升闪烁鸡尾酒悬浮。[3H]胸苷吸收使用TriCarb 2100TR液体闪烁分析器(PackardBioScience Company，IL)被定量为每分钟计数(CPM)，计数归一化为CPM/10,000细胞，以说明PBL浓度的变化。
谷氨酰胺对淋巴细胞增殖的作用
伴刀豆球蛋白A(Con A)为多克隆T细胞促分裂素。在Con A促分裂素的存在下，全面分析表明膳食(无Con A剂量的效应)、或由Con A相互作用的膳食处置的显著作用。因此，在不同剂量Con A范围内压缩数据以表明随着膳食中谷氨酰胺的增补百分数的不同而变化的淋巴细胞的增殖反应。
表4：T细胞淋巴细胞响应Con A促分裂素的增殖
| 食品 | T细胞增殖(log10cpm) |
| 未增补谷氨酰胺 | 4.7 |
| 增补1％的谷氨酰胺 | 5 |
| 增补2％的谷氨酰胺 | 4.8 |
| 增补4％的谷氨酰胺 | 4.5 |
膳食处置有显著性主要效应(P＜0.01)。增补1％谷氨酰胺的膳食表现出最大的淋巴细胞增殖，其显著不同于对照组(p＜0.05)。供给1％和2％谷氨酰胺的狗表现出淋巴细胞增殖的类似增加。在这些组和其膳食中增补有4％谷氨酰胺的动物中的淋巴细胞的增殖反应之间具有显著性差异(P＜0.01)，由此表明增补1-2％的谷氨酰胺增强总的T淋巴细胞增殖。然而，4％谷氨酰胺在这方面没有附加的益处。
Claims (14)
1.在患有胃肠道炎症的哺乳动物中适合于哺乳动物口服摄取的组合物，其包括抗腹泻有效量的谷氨酰胺、发酵性纤维、抗氧化剂和ω-3脂肪酸。
2.权利要求1的组合物，其中哺乳动物为狗或猫。
3.权利要求2的组合物，其中组合物以狗或猫的膳食形式被给用。
4.权利要求3的组合物，其中谷氨酰胺为膳食的约0.1到约5重量％。
5.权利要求3的组合物，其中发酵性纤维为膳食的约0.5到约20重量％。
6.权利要求3的组合物，其中抗氧化剂为膳食的约0.1到约3重量％。
7.权利要求3的组合物，其中ω-3脂肪酸为膳食的约0.1到约3重量％。
8.权利要求4的组合物，其中发酵性纤维为膳食的约0.5到约20重量％。
9.权利要求4的组合物，其中抗氧化剂为膳食的约0.1到约3重量％。
10.权利要求4的组合物，其中ω-3脂肪酸为膳食的约0.1到约3重量％。
11.权利要求8的组合物，其中抗氧化剂为膳食的约0.1到约3重量％。
12.权利要求8的组合物，其中ω-3脂肪酸为膳食的约0.1到约3重量％。
13.权利要求11的组合物，其中ω-3脂肪酸为膳食的约0.1到约3重量％。
14.用于处置患有胃肠道炎症的哺乳动物中的腹泻的方法，包括对所述哺乳动物口服给用权利要求1的组合物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/729,450 | 2003-12-05 | ||
| US10/729,450 US7754677B2 (en) | 2003-12-05 | 2003-12-05 | Composition and method for reducing diarrhea in a mammal |
| PCT/US2004/040679 WO2005055737A1 (en) | 2003-12-05 | 2004-12-03 | Anti-diarrhea composition containing glutamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1889853A true CN1889853A (zh) | 2007-01-03 |
| CN1889853B CN1889853B (zh) | 2010-10-27 |
Family
ID=34633941
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2004800360410A Expired - Fee Related CN1889853B (zh) | 2003-12-05 | 2004-12-03 | 包含谷氨酰胺的抗腹泻组合物 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7754677B2 (zh) |
| EP (1) | EP1696735B2 (zh) |
| JP (1) | JP5698427B2 (zh) |
| CN (1) | CN1889853B (zh) |
| AT (1) | ATE445332T1 (zh) |
| AU (1) | AU2004296213B2 (zh) |
| BR (1) | BRPI0417188A (zh) |
| CA (1) | CA2547005C (zh) |
| DE (1) | DE602004023648D1 (zh) |
| DK (1) | DK1696735T4 (zh) |
| ES (1) | ES2333796T5 (zh) |
| MX (1) | MXPA06005946A (zh) |
| RU (1) | RU2370098C2 (zh) |
| WO (1) | WO2005055737A1 (zh) |
| ZA (1) | ZA200604542B (zh) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101715907B (zh) * | 2009-11-20 | 2012-06-27 | 长沙绿叶生物科技有限公司 | 一种有利于猪、犬肠道健康和护理的保健饲料及其应用 |
| CN102573798A (zh) * | 2009-08-05 | 2012-07-11 | 雀巢产品技术援助有限公司 | 改善胃肠健康的方法和组合物 |
| CN108079001A (zh) * | 2017-12-26 | 2018-05-29 | 中国药科大学 | 木聚糖酯化产物在制备预防或治疗炎症性疾病及癌症药物中的应用 |
| CN111329997A (zh) * | 2020-03-04 | 2020-06-26 | 山东信得科技股份有限公司 | 一种治疗猫炎症性肠道疾病的软咀嚼片剂及其制备方法 |
| CN113749189A (zh) * | 2021-09-22 | 2021-12-07 | 内蒙古自治区农牧业科学院 | 一种减缓反刍动物胃肠道炎症的营养素功能包 |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101351124B (zh) * | 2005-12-29 | 2014-09-03 | 希尔氏宠物营养品公司 | 用于改变动物的肠道菌群的方法 |
| ITMI20062031A1 (it) * | 2006-10-23 | 2008-04-24 | Velleja Res Srl | Composizioni per la prevenzione del depauperamento della flora intestinale e del danno d'organo successivi a terapia antibiotica |
| EP2156846B1 (en) * | 2007-05-08 | 2014-08-13 | Ajinomoto Co., Inc. | Prophylactic or therapeutic agent for diarrhea |
| EP3476226B1 (en) * | 2016-06-24 | 2024-05-22 | Yessinergy Holding s/a | Immunomodulating and growth-promoting composition controlling the population of undesirable bacteria in the intestinal microbiota |
| EP3603420A4 (en) * | 2017-03-28 | 2021-04-14 | Ajinomoto Co., Inc. | FOOD TO IMPROVE THE INTRAINTESTINAL ENVIRONMENT |
| WO2021207755A1 (en) * | 2020-04-06 | 2021-10-14 | Hill's Pet Nutrition, Inc. | Pet food compositions |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US616355A (en) * | 1898-12-20 | Locomotive-coaling device | ||
| JPS61167622A (ja) * | 1985-01-22 | 1986-07-29 | Asahi Breweries Ltd | 糖尿病コントロ−ル剤 |
| JP2549638B2 (ja) | 1986-10-30 | 1996-10-30 | サントリー株式会社 | ビフイズス菌増殖促進組成物 |
| US5294458A (en) | 1992-04-03 | 1994-03-15 | Maruha Corporation | Pet food |
| JPH07118162A (ja) * | 1991-10-09 | 1995-05-09 | Kyodo Shiryo Kk | 家畜用経口投与組成物 |
| JPH06211653A (ja) * | 1993-01-13 | 1994-08-02 | Snow Brand Milk Prod Co Ltd | ω─３系列の脂肪酸を含有する油脂を有効成分とする下痢防止治療剤 |
| GB9403935D0 (en) * | 1994-03-01 | 1994-04-20 | Sandoz Nutrition Ltd | Improvements in or relating to organic compounds |
| US5616569A (en) * | 1994-03-28 | 1997-04-01 | The Iams Company | Pet food product containing fermentable fibers and process for treating gastrointestinal disorders |
| US5444054A (en) | 1994-04-01 | 1995-08-22 | Abbott Labatories | Method of treating ulcerative colitis |
| US6241983B1 (en) | 1994-10-28 | 2001-06-05 | Metagenics, Inc. | Bacteria-and fiber-containing composition for human gastrointestinal health |
| US5531989A (en) | 1994-10-28 | 1996-07-02 | Metagenics, Inc. | Immunoglobulin and fiber-containing composition for human gastrointestinal health |
| JPH09201A (ja) * | 1995-06-23 | 1997-01-07 | Akikuni Yakida | 炎症性腸疾患用食品 |
| JP3488544B2 (ja) * | 1995-07-28 | 2004-01-19 | 明治乳業株式会社 | 分泌性下痢予防食品及び分泌性下痢防止剤 |
| FR2756181B1 (fr) | 1996-11-26 | 1999-03-05 | Au Mont Beaute | Composition cosmetique, pharmaceutique a base de culture inactivee de bacteries bifidobacterium, d'huile de menthe et d'un acide |
| US5952033A (en) | 1996-12-24 | 1999-09-14 | Nestec S.A. | Gelatinized cereal product containing oligosaccharide and processes of preparing and using same |
| PT862863E (pt) | 1997-01-09 | 2002-04-29 | Nestle Sa | Produto cerealifero contendo probioticos |
| TR200000021T2 (tr) | 1997-07-05 | 2001-01-22 | Societe Des Produits Nestle S.A. | Bağırsak hücreleri tarafından minerallerin emilmesi. |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| US6051260A (en) | 1998-04-07 | 2000-04-18 | Healthcomm International, Inc. | Medical food composition of reduced allergenicity, especially adapted for improving gut mucosal integrity |
| US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
| IT1304170B1 (it) | 1998-12-15 | 2001-03-08 | Novartis Nutrition Ag | Composti organici |
| GB9901809D0 (en) | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
| DE19911053B4 (de) * | 1999-03-12 | 2004-10-28 | Biotec Asa | Kosmetische und/oder pharmazeutische Zubereitungen |
| US6706287B2 (en) | 2001-05-15 | 2004-03-16 | Kibow Biotech Inc. | Prebiotic and probiotic compositions and methods for their use in gut-based therapies |
| JP2001008638A (ja) * | 1999-06-25 | 2001-01-16 | Teikuoo:Kk | 競走馬又は家畜用飼料 |
| US6468525B1 (en) | 1999-08-10 | 2002-10-22 | Renew Life, Inc. | Probiotic formulation |
| US6737089B2 (en) * | 1999-08-27 | 2004-05-18 | Morinda, Inc. | Morinda citrifolia (Noni) enhanced animal food product |
| US6248375B1 (en) * | 2000-03-14 | 2001-06-19 | Abbott Laboratories | Diabetic nutritionals and method of using |
| DE10021384A1 (de) | 2000-05-03 | 2001-11-15 | Hora Reiner | Ergänzungsfutter für Haustiere |
| US6592863B2 (en) | 2000-08-22 | 2003-07-15 | Nestec S.A. | Nutritional composition |
| JP2002154977A (ja) * | 2000-09-05 | 2002-05-28 | Kao Corp | 飲食用組成物 |
| JP2002226369A (ja) * | 2001-01-30 | 2002-08-14 | Otsuka Pharmaceut Co Ltd | グルタミン含有経口組成物 |
| JP3510861B2 (ja) * | 2001-01-31 | 2004-03-29 | リバテープ製薬株式会社 | 美容食品 |
-
2003
- 2003-12-05 US US10/729,450 patent/US7754677B2/en not_active Expired - Lifetime
-
2004
- 2004-12-03 AU AU2004296213A patent/AU2004296213B2/en not_active Ceased
- 2004-12-03 WO PCT/US2004/040679 patent/WO2005055737A1/en active Application Filing
- 2004-12-03 DK DK04813066.0T patent/DK1696735T4/da active
- 2004-12-03 EP EP04813066.0A patent/EP1696735B2/en not_active Not-in-force
- 2004-12-03 CA CA2547005A patent/CA2547005C/en not_active Expired - Fee Related
- 2004-12-03 DE DE602004023648T patent/DE602004023648D1/de active Active
- 2004-12-03 MX MXPA06005946A patent/MXPA06005946A/es active IP Right Grant
- 2004-12-03 BR BRPI0417188-8A patent/BRPI0417188A/pt not_active Application Discontinuation
- 2004-12-03 CN CN2004800360410A patent/CN1889853B/zh not_active Expired - Fee Related
- 2004-12-03 AT AT04813066T patent/ATE445332T1/de not_active IP Right Cessation
- 2004-12-03 RU RU2006123946/13A patent/RU2370098C2/ru not_active IP Right Cessation
- 2004-12-03 JP JP2006542830A patent/JP5698427B2/ja active Active
- 2004-12-03 ES ES04813066.0T patent/ES2333796T5/es active Active
-
2006
- 2006-06-02 ZA ZA200604542A patent/ZA200604542B/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102573798A (zh) * | 2009-08-05 | 2012-07-11 | 雀巢产品技术援助有限公司 | 改善胃肠健康的方法和组合物 |
| CN101715907B (zh) * | 2009-11-20 | 2012-06-27 | 长沙绿叶生物科技有限公司 | 一种有利于猪、犬肠道健康和护理的保健饲料及其应用 |
| CN108079001A (zh) * | 2017-12-26 | 2018-05-29 | 中国药科大学 | 木聚糖酯化产物在制备预防或治疗炎症性疾病及癌症药物中的应用 |
| CN111329997A (zh) * | 2020-03-04 | 2020-06-26 | 山东信得科技股份有限公司 | 一种治疗猫炎症性肠道疾病的软咀嚼片剂及其制备方法 |
| CN113749189A (zh) * | 2021-09-22 | 2021-12-07 | 内蒙古自治区农牧业科学院 | 一种减缓反刍动物胃肠道炎症的营养素功能包 |
Also Published As
| Publication number | Publication date |
|---|---|
| DK1696735T3 (da) | 2010-01-18 |
| CA2547005A1 (en) | 2005-06-23 |
| EP1696735B1 (en) | 2009-10-14 |
| AU2004296213A1 (en) | 2005-06-23 |
| EP1696735A1 (en) | 2006-09-06 |
| BRPI0417188A (pt) | 2007-03-06 |
| JP5698427B2 (ja) | 2015-04-08 |
| EP1696735B2 (en) | 2014-06-11 |
| RU2006123946A (ru) | 2008-01-10 |
| US7754677B2 (en) | 2010-07-13 |
| CN1889853B (zh) | 2010-10-27 |
| ES2333796T5 (es) | 2014-09-30 |
| US20050124576A1 (en) | 2005-06-09 |
| DK1696735T4 (da) | 2014-09-29 |
| WO2005055737A1 (en) | 2005-06-23 |
| ZA200604542B (en) | 2007-11-28 |
| CA2547005C (en) | 2012-10-16 |
| RU2370098C2 (ru) | 2009-10-20 |
| AU2004296213B2 (en) | 2010-09-23 |
| ES2333796T3 (es) | 2010-03-01 |
| MXPA06005946A (es) | 2006-07-06 |
| JP2007519620A (ja) | 2007-07-19 |
| DE602004023648D1 (de) | 2009-11-26 |
| ATE445332T1 (de) | 2009-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200604542B (en) | Anti-diarrhea composition containing glutamine | |
| Newbold et al. | Changes in the microbial population of a rumen-simulating fermenter in response to yeast culture | |
| Nogueira et al. | Dietary supplementation of a fiber-prebiotic and saccharin-eugenol blend in extruded diets fed to dogs | |
| AU753097B2 (en) | Composition for improving glucose and insulin metabolism in companion animals | |
| CN1202735C (zh) | 宠物食品组合物 | |
| Van Nevel et al. | Incorporation of galactomannans in the diet of newly weaned piglets: effect on bacteriological and some morphological characteristics of the small intestine | |
| Safari et al. | Dietary administration of eryngii mushroom (Pleurotus eryngii) powder on haemato-immunological responses, bactericidal activity of skin mucus and growth performance of koi carp fingerlings (Cyprinus carpio koi) | |
| AU2008229785B2 (en) | Methods and kits related to administration of a fructooligosaccharide | |
| EP2570034B1 (en) | Feed for aquacultural animals | |
| CN1498082A (zh) | 用碳水化合物源限制猫体重增加 | |
| RU2375065C2 (ru) | Способ уменьшения запаха экскрементов у домашних животных | |
| Juśkiewicz et al. | Performance and gastrointestinal tract metabolism of turkeys fed diets with different contents of fructooligosaccharides | |
| US6641836B2 (en) | Process for enhancing immune response in canines using a dietary composition including garlic | |
| Luo et al. | Fermented alfalfa meal instead of “grain-type” feedstuffs in the diet improves intestinal health related indexes in weaned pigs | |
| DOS SANTOS et al. | Effects of dietary fiber on growth performance, fecal ammonia nitrogen | |
| Nurfitriani et al. | Effects of bionanomineral selenium (BioNano-Se) and probiotics inclusion to ration on in vitro rumen fermentation characteristics. | |
| Gai et al. | Future Challenges in Rabbit Nutrition | |
| Chumpawadee et al. | Effect of level of cassava pulp in fermented total mixed ration on feed intake, nutrient digestibility, ruminal fermentation and chewing behavior in goats. | |
| Yahav et al. | Cholecalciferol supplementation alters gut function and improves digestibility in an underground inhabitant, the naked mole rat (Heterocephulus gluber), when fed on a carrot diet | |
| Sanderson | Prebiotics for gastrointestinal health. | |
| Abdelhamid et al. | Effect of feeding sheep on naturally spoiled rice straw, clover hay and concentrate feed mixtures | |
| AA et al. | EFFECT OF SYNBIOTIC SUPPLEMENTATION OF HIGH FIBRE DIET ON GROWTH PERFORMANCE, NUTRIENT DIGESTIBILITY, INTESTINAL MICROBIAL ECOLOGY AND HISTOMORPHOLOGY OF BROILER CHICKENS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101027 Termination date: 20181203 |